Vertex Kidney Drug Shows Promise
Vertex Pharmaceuticals reported its kidney disease therapy reduced a key biomarker by 52% in Phase 3 trials, boosting the stock.
The drug, known as povetacicept, led to a 49.8% reduction in the urine protein to creatinine ratio (UPCR) compared to a placebo. Vertex aims to complete its FDA submission by the end of March and could potentially receive accelerated approval in November. This positions povetacicept to compete with Otsuka's Voyxact, the first anti-APRIL drug approved for IgAN, and Vera Therapeutics' atacicept, which has a potential FDA approval date in July. BMO analysts suggest povetacicept's efficacy across patient subgroups could give it a competitive edge. Analysts are generally positive about Vertex's data, with Citi analysts raising the probability of approval to 90%. The average analyst price target for Vertex Pharmaceuticals is around $552, suggesting a potential upside from the current price. Oppenheimer recently raised its price target to $600. Vertex acquired povetacicept in a $4.9 billion deal in 2024, viewing it as a potential "best-in-class" therapy. The company also intends to expand the drug into generalized myasthenia gravis.
